Will there be metastasis after taking tucatinib/tucatinib?

Tucatinib/Tucatinib is an oral, potent and selective HER2-specific targeting agent approved by the U.S. Food and Drug Administration (FDA) in April 2020 for the treatment of advanced unresectable or metastatic breast cancer (mBC). In a preclinical study and phase I clinical trial, tucatinib showed promising activity as a single agent and increased effectiveness when combined with chemotherapy or trastuzumab. In-depth research on the signaling mechanism shows that unlike other TKIs (such as lapatinib and neratinib, which are dual inhibitors of EGFR and HER2), tucatinib is a specific reversible inhibitor of HER2 protein tyrosine kinase (PTK) activity and has minimal inhibitory effect on EGFR.

Tucatinib is not a panacea. Although it has shown significant efficacy in the treatment ofHER2-positive breast cancer, it does not guarantee complete prevention of tumor metastasis. Even if the growth of the primary tumor is controlled by drugs such as tucatinib, there may still be trace amounts of cancer cells that escape the control of the drug and metastasize. The risk of tumor metastasis is also affected by various factors such as individual patient differences, tumor stage and pathological type. Different patients have different tumor growth rates, invasive capabilities, and sensitivity to drugs.

The therapeutic effect of tucatinib also depends on factors such as the way the drug is used and its dosage. During the use of tucatinib, it is necessary to strictly follow the doctor's recommendations and guidance to ensure the correct use and dosage control of the drug. Otherwise, the drug may be ineffective or produce adverse reactions, thereby increasing the risk of tumor metastasis. Therefore, during the treatment process, patients need to actively cooperate with the doctor's treatment plan, conduct regular review and monitoring, and promptly detect and deal with possible metastatic lesions.